The rising prevalence of chronic diseases, such as cancer and neurological disorders, has driven the demand for advanced diagnostic tools in Australia. Positron Emission Tomography (PET) imaging, renowned for its high-resolution imaging capabilities, plays a vital role in diagnosing oncology, neurology, and cardiology conditions. Several key players are collaborating to deliver precision-focused products for PET imaging. Against this backdrop, Australia’s PET imaging systems market is anticipated to experience notable growth, with a projected compound annual growth rate (CAGR) of approximately 3.6% through 2023-2033, forecasts GlobalData, a leading data, and analytics company.
According to GlobalData’s report, “Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033,” the number of PET scans performed in Australia will witness a CAGR of 2.2% during 2023-2033, reflecting an increasing reliance on these systems for accurate diagnostic outcomes.
Recently, Australia-based Telix Pharmaceuticals has partnered with California’s Subtle Medical, Inc. to integrate artificial intelligence (AI) into PET imaging. This collaboration focuses on using Subtle Medical’s AI-powered solutions with Telix’s commercial PSMA-PET product, Illuccix, aiming to enhance image precision, shorten scan durations, and streamline workflow.
Jyoti Sharma, Medical Devices Analyst at GlobalData, comments: “Traditional PET systems often face challenges related to prolonged scan times, which can lead to inefficiencies and patient discomfort. The integration of AI-powered solutions is a game-changer, offering innovative ways to optimize workflows and meet the growing demand for diagnostic services.”
The integration of AI addresses the challenges associated with traditional systems by enabling faster PET scans, saving time without compromising image quality. This advancement not only enhances diagnostic precision but also reduces patient wait times and improves comfort, contributing to a better overall healthcare experience.
Sharma concludes: “AI-powered innovations are a transformative step for PET imaging in Australia. By enhancing efficiency and reducing scan times, they make PET imaging a more viable and better option compared to other technologies. As a result, the future of the market will be shaped by data-driven approaches and innovative technologies.”
